Pacific Biosciences of California (PACB) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.27 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 15%. A quarter ago, it was expected that this maker of genetic analysis technology would post a loss of $0.24 per share when it actually produced a loss of $0.20, delivering a surprise of 16.67%.Over the ...

Exhibit 99.1 PacBio Announces Third Quarter 2024 Financial Results MENLO PARK, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) – PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2024. Third quarter results: • Revenue of $40.0 million compared with $55.7 million in the prior-year period. • Instrument revenue of $16.8 million compared with $34.7 million in the prior-year period. Instrument revenue in the third quarter of 2024 included 22 Revio sequencing systems. • Consumable ...

MENLO PARK, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world’s most advanced sequencing technologies, today announced the Vega™ system, the company’s first benchtop long-read sequencing platform. Vega delivers all the functionality of the Revio system, PacBio’s high-throughput long-read sequencer, into a compact, lower-throughput benchtop platform. Offering exceptional data accuracy with HiFi technology, fast turnaround time, and a U.S. list price of $169,000, Vega is ...

MENLO PARK, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- PacBio (Nasdaq: PACB), a leading developer of high-quality, highly accurate genomic sequencing solutions, today announced the inclusion of the Onso short-read sequencing platform in the 10x Genomics Compatible Partner Program. The 10x Genomics Compatible Partner Program recognizes instruments and workflows compatible with 10x Genomics’ products and applications, thereby broadening the range of sequencing solutions available to researchers worldwide. The ...

Pacific Biosciences of California (PACB) closed the latest trading day at $2.06, indicating a -1.9% change from the previous session's end. The stock fell short of the S&P 500, which registered a gain of 0.47% for the day. Elsewhere, the Dow saw an upswing of 0.79%, while the tech-heavy Nasdaq appreciated by 0.28%. Shares of the maker of genetic analysis technology witnessed a gain of 12.3% over the previous month, beating the performance of the Medical sector with its loss of 4.27% and the S&P 500's gain o ...

Pacific Biosciences of California, Inc. (PACB) , popularly known as PacBio, has been gaining from its continued focus on research and development. The optimism, led by decent second-quarter 2024 earnings and product development activities, is expected to contribute further. However, stiff competition and macroeconomic concerns persist. In the year-to-date period, this Zacks Rank #3 (Hold) company's shares have lost 79.1% against 6.6% growth of the industry. The S&P 500 composite has also gained 21.9% in the ...

Pacific Biosciences, Inc. (PACB) , popularly known as PacBio, has signed a new Research Collaboration Agreement with the National Cancer Centre of Singapore (NCCS) to enhance Asian cancer research. Leveraging PacBio's Onso short-read sequencing platform, the collaboration aims to enable researchers to profile the genomic landscape of prevalent cancers, including gastrointestinal stromal tumors. PacBio's partner, Diethelm Keller Siber Hegner (DKSH), a Swiss company specializing in market expansion services, ...

SINGAPORE, Oct. 11, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the signing of a new Research Collaboration Agreement (RCA) with the National Cancer Centre of Singapore (NCCS). This collaboration aims to accelerate cancer research by leveraging PacBio's advanced sequencing technologies, including the innovative Onso short-read sequencing platform, to profile the genomic landscape of prevalent cancers in Asia. The ...

MENLO PARK, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its third quarter 2024 financial results on Thursday, November 7, 2024, at 4:30 pm Eastern Time. The call will be webcast and may be accessed at PacBio's website at https://investor.pacificbiosciences.com/. Date: Thursday, November 7, 2024, at 4:30 pm ET (1:30 pm PT) Listen live via internet or replay: https://investor.pacificbiosciences.com/ Toll-free: 1-888 ...

The most recent trading session ended with Pacific Biosciences of California (PACB) standing at $1.81, reflecting a +0.56% shift from the previouse trading day's closing. The stock outperformed the S&P 500, which registered a daily gain of 0.54%. At the same time, the Dow added 0.72%, and the tech-heavy Nasdaq gained 0.65%. Prior to today's trading, shares of the maker of genetic analysis technology had gained 6.51% over the past month. This has outpaced the Medical sector's gain of 4.37% and the S&P 500's ...